Loncar Cancer Immunotherapy ETF (CNCR)
$9.02+0.00%Close
Snapshot
- 1 week
- 0.0%+2.0% vs SPY
- 1 month
- -11.3%-12.8% vs SPY
- Market cap
- $7.0M
Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year
Price & returns: 3 years, 5 years
Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)
Signal evidence
Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company
About
Loncar Cancer Immunotherapy ETF (CNCR). This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this…
SEC filingsCIK 1540305
Profile
SectorFinancial Services
IndustryAsset Management
ExchangeNASDAQ
CountryUS
CEO-
IPOOct 14, 2015
Employees-
Shares outstanding780.8K
Float0
Free float0.0%
Company news
Loading headlines…